rs12693542 — SLC40A1

SLC40A1 — The Brain's Iron Export Gate and Restless Legs Syndrome

Every neuron, including the dopamine-producing cells of the substantia nigra¹¹ substantia nigra
The midbrain region housing dopaminergic neurons whose iron stores are consistently reduced in restless legs syndrome even when blood iron is normal, depends on a steady supply of iron to sustain normal function. But iron cannot simply diffuse into the brain — it must cross specialized barriers, and the protein that controls its export from cells along this route is ferroportin²² ferroportin
The sole known mammalian iron exporter, encoded by SLC40A1 on chromosome 2, expressed on enterocytes, macrophages, and critically the choroid plexus epithelial cells and ependymal cells lining the brain's ventricles. The rs12693542 variant sits approximately two kilobases upstream of the SLC40A1 gene in a regulatory region, where it influences how much ferroportin the cell produces. The G allele — a minority variant in most populations — is associated with increased susceptibility to restless legs syndrome³³ restless legs syndrome
Also called Willis-Ekbom disease; a neurological condition causing irresistible urges to move the legs, typically at rest and worst in the evening, affecting 5-10% of adults.

The Mechanism

Restless legs syndrome is not, as was long assumed, primarily a dopamine disorder. Post-mortem neuropathology⁴⁴ Post-mortem neuropathology
Connor JR et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 2003 consistently shows iron-deficient substantia nigra in RLS brains, but the cellular machinery looks normal: no dopaminergic degeneration, no Lewy bodies. The iron simply isn't getting in. The iron stores of [neuromelanin cells | Pigmented dopamine-producing neurons in the substantia nigra that normally accumulate large iron deposits through the lifespan] — which normally accumulate iron throughout life — are markedly depleted in RLS brains compared to age-matched controls.

The route iron takes into the brain is circuitous. Iron from the bloodstream enters [choroid plexus | A network of epithelial cells in the brain's ventricles that produces cerebrospinal fluid and acts as a selective iron gateway into the CNS] epithelial cells, crosses those cells, and is then exported via ferroportin into cerebrospinal fluid, which delivers iron to brain tissue. A second route crosses the blood-brain barrier microvasculature. Studies of RLS brains⁵⁵ Studies of RLS brains
Connor JR et al. Profile of altered brain iron acquisition in restless legs syndrome. Brain, 2011 found paradoxically elevated ferroportin in the choroid plexus of RLS patients — a likely compensatory response to the iron-deficient brain environment — alongside reduced IRP1 activity, suggesting dysregulated cellular iron sensing.

Critically, laser capture microdissection⁶⁶ laser capture microdissection
Connor JR et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology, 2004 of individual neuromelanin cells from RLS substantia nigra found reduced ferroportin, reduced transferrin receptor, reduced H-ferritin, and reduced IRP1 protein — a signature of cellular iron starvation despite the compensatory upregulation at the choroid plexus. The upstream variant rs12693542 presumably modulates the baseline expression of SLC40A1, shifting the equilibrium of this already-fragile brain iron delivery system.

Hepcidin-ferroportin signaling⁷⁷ Hepcidin-ferroportin signaling
Clardy SL et al. Is ferroportin-hepcidin signaling altered in restless legs syndrome? J Neurol Sci, 2006 is also disrupted in RLS — pro-hepcidin was significantly decreased in CSF of early-onset RLS patients, while brain tissue showed elevated pro-hepcidin in the substantia nigra and putamen. This bidirectional hepcidin dysregulation compounds any genetically reduced ferroportin expression, creating a milieu in which the brain chronically under-delivers iron to precisely the neurons that need it.

The Evidence

The Schormair et al. 2024 meta-analysis⁸⁸ Schormair et al. 2024 meta-analysis
Schormair B et al. Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. Nature Genetics, 2024 represents the definitive population genetics study of RLS to date — 116,647 cases and 1,546,466 controls of European ancestry, increasing the total genome-wide significant loci from 20 to 164. rs12693542 in the SLC40A1 regulatory region reached p=1.35×10⁻¹³, comfortably beyond genome-wide significance (p<5×10⁻⁸). This places it among the most robustly replicated common genetic risk factors for RLS, and directly implicates the ferroportin expression axis in disease pathogenesis.

The biological plausibility is high. Multiple independent lines of evidence converge: the neuropathological iron deficiency in RLS substantia nigra, the aberrant ferroportin expression at the blood-brain interface, the disrupted hepcidin-ferroportin signaling in RLS CSF and brain tissue, and now the GWAS signal upstream of the gene encoding ferroportin itself.

Practical Actions

The clinical implications follow directly from the pathophysiology. Iron therapy is an established first-line treatment for RLS when serum ferritin is low, and even in patients with "normal" peripheral iron. Current guidelines recommend iron supplementation when ferritin is below 75 µg/L, as clinical trials reviewed by Trenkwalder et al.⁹⁹ clinical trials reviewed by Trenkwalder et al.
Trenkwalder C et al. Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, 2018 demonstrate that intravenous iron preparations (ferric carboxymaltose, ferric gluconate) significantly reduce RLS symptom severity. The therapeutic target for brain iron delivery is a serum ferritin well above the lower limit of the normal reference range — typically 100-150 µg/L for optimal neurological iron availability.

Oral iron supplementation is also effective for milder cases. Iron bisglycinate is better tolerated and has higher bioavailability than ferrous sulfate. Ferritin should be monitored at 3-month intervals when supplementing to track response and avoid overcorrection.

Importantly, the brain iron deficit in RLS is not simply a mirror of peripheral iron status. Some RLS patients have normal serum ferritin yet still respond to iron therapy, suggesting that the genetic variants affecting iron transport at the blood-brain interface — including SLC40A1 regulatory variants — create a CNS-specific iron insufficiency that is only partially captured by serum ferritin.

Interactions

rs12693542 operates within the broader iron homeostasis network. Three key interaction partners are represented elsewhere in the GeneOps database:

HFE variants rs1800562 (C282Y) and rs1799945 (H63D) cause hereditary hemochromatosis by raising serum iron — paradoxically, some hemochromatosis patients can still have RLS if brain iron delivery is impaired despite elevated peripheral iron. The combination of HFE iron overload genotype with the SLC40A1 upstream risk allele (reduced ferroportin expression) creates opposing pressures on the systemic versus neurological iron axis.

TMPRSS6 rs855791 (Ala736Val) affects hepcidin suppression and iron absorption efficiency. Individuals carrying both the TMPRSS6 A allele (reduced iron absorption) and the SLC40A1 G allele (impaired brain iron delivery) face compounded disadvantage: less iron in the bloodstream to begin with, and less efficient delivery to the CNS. This compound exposure likely represents the highest-risk subgroup for RLS driven by iron insufficiency.